Search the Newsreel

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger …

Top Odyssey Therapeutics (ODTX) Competitors 2026

This article analyzes Odyssey Therapeutics (ODTX) against five of its biotechnology competitors: Relay Therapeutics (RLAY), Alumis (ALMS), Arcus Biosciences (RCUS), Legend Biotech (LEGN), and Telix Pharmaceuticals (TLX). MarketBeat compares these companies based on various financial metrics, analyst ratings, profitability, and media sentiment to help …

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has increased its price target for Odyssey Therapeutics (NASDAQ:ODTX) to $29.00 from $26.00, maintaining an "overweight" rating and suggesting a potential upside of 32.12%. This positive outlook is supported by a "Moderate Buy" consensus rating from analysts and recent insider …

Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary

Odyssey Therapeutics, Inc. reported Q2 2026 results, showing $0 revenue and a net loss of $52.8M, or $(1.74) EPS. The company noted a shift from collaboration revenue and stated that proceeds from its IPO and a private placement extend its cash runway into the …

Odyssey Therapeutics (Nasdaq: ODTX) reports $91.1M loss, $433.1M cash

Odyssey Therapeutics (ODTX) reported a net loss of $91.1 million for the first half of 2026, an increase from $79.7 million in the same period last year, primarily due to continued investment in its pipeline and higher non-cash contingent consideration expense. Following a May …

Biotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS

(RTTNews) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports. Bioventus Inc. (BVS) Bioventus is a medical device company that focuses on technology for pain management and musculoskeletal issues. The company touched a 52-week …

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet …

Odyssey Therapeutics Inc: Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics reported its second-quarter 2026 financial results, highlighted by positive clinical proof-of-concept data for its OD-001 program and plans to advance it into Phase 2b monotherapy and Phase 2a combination trials later in 2026. The company also expects to file a Clinical Trial …

Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026

Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX